Pancreatic cancer
Conditions
Interventions
Gemcitabine Hydrochloride 1000 mg/m2 as Gemcitabine by drip infusion for 30 minutes Once a week for 3 weeks One course takes 4 weeks Maximum 6 courses Krestin 3 g per day 3 times per day D
Sponsors
Kyoto University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with invasive ductal pancreatic cancer. 2)Patients with resection of the primary lesion and final findings stage III or IVa. 3)Patients who is between 20 and 80 years old at the time of enrollment. 4)Patients with ECOG Performance Status Scale of 0 or 1. 5)Patients without receiving chemotherapy, radiation therapy and immunotherapy including the treatment for the other carcinoma. 6)Patients who can take medicine orally. 7)Patients who maintain function of main organ in clinical test within 14 days before enrollment. 8)Patients with starting the immunochemotherapy within 2 weeks after enrollment. 9)Patients who have given consent to participate in this clinical study.
Exclusion criteria
Exclusion criteria: 1) Active double cancer. 2) Patients with severe myelosuppression. 3) Patients who receiving radiation therapy to the chest. 4) Patients with severe infection. 5) Patients with pulmonary fibrosis or interstitial lung disease. 6) Pregnant patients. 7) Patients with insanity or psychological symptom.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Overall survival 2) Incidence of adverse event | — |
Countries
Japan
Contacts
Public ContactKyoichi Takaori
Kyoto University Hospital Department of Hepato-Pancreatic Surgery & Transplantation
Outcome results
None listed